Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)

Nancy H. L. Leung*[1,2], Samuel M. S. Cheng*[1], Carolyn A. Cohen*[3], Mario Martín-Sánchez[1],

Niki Y. M. Au[1], Leo L. H. Luk[1], Leo C. H. Tsang[1], Kelvin K. H. Kwan[1], Sara Chaothai[1], Lison

W. C. Fung[1], Alan W. L. Cheung[3], Karl C. K. Chan[1], John K. C. Li[1], Yvonne Y. Ng[1],

Prathanporn Kaewpreedee[3], Janice Z. Jia[3], Dennis K. M. Ip[1], Leo L. M. Poon[1,3,4], Gabriel M.

Leung[†1,2], J. S. Malik Peiris[†1,3,4], Sophie A. Valkenburg[†3,5], Benjamin J. Cowling[†1,2]

*Joint first authors with equal contribution

†Joint senior authors with equal contribution

#Corresponding authors

Affiliations:

1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of

Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong

Special Administrative Region, China.

2. Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, New

Territories, Hong Kong Special Administrative Region, China.

3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The

University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.

4. Centre for Immunology and Infection; Hong Kong Science and Technology Park, New

Territories, Hong Kong Special Administrative Region, China.

5. Department of Microbiology and Immunology, Peter Doherty Institute of Infection and

Immunity, The University of Melbourne, Melbourne, Victoria, Australia.

Clinicaltrials.gov registration: NCT05057169

Running head: Crossover trial of CoronaVac and BNT162b2

Word count (abstract): 301

Word count (main text): 4,500

Corresponding authors:

Benjamin Cowling, WHO Collaborating Centre for Infectious Disease Epidemiology and

Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong;

Hong Kong Special Administrative Region, China. bcowling@hku.hk

Nancy Leung, WHO Collaborating Centre for Infectious Disease Epidemiology and Control,

School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong

Special Administrative Region, China. leungnan@hku.hk

ABSTRACT

Background: There are few trials comparing homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines and mRNA vaccines.

Methods: We conducted an open-label randomized trial in adults >=18 years of age who received two doses of inactivated vaccine (CoronaVac) or mRNA vaccine (BNT162b2) >=6 months earlier, randomised in 1:1 ratio to receive a third dose of either vaccine. We compared the reactogenicity, immunogenicity and cell-mediated immune responses, and assessed vaccine efficacy against infections during follow-up.

Results: We enrolled 219 adults who previously received two doses of CoronaVac and randomised to CoronaVac ("CC-C", n=101) or BNT162b2 ("CC-B", n=118) third dose; and 232 adults who previously received BNT162b2 and randomised to CoronaVac ("BB-C", n=118) or BNT162b2 ("BB-B", n=114). There were more frequent reports of mild reactions in recipients of third-dose BNT162b2, which generally subsided within 7 days. Third doses significantly increased neutralising $PRNT_{50}$ antibody titers against ancestral virus and Omicron BA.1 variant in all four study arms, and against Omicron BA.2 in all arms except CC-C, with statistically significant improvements for recipients of a third dose of BNT162b2 over CoronaVac irrespective of prior vaccine type. Boosting of $CD4^+$ T cells only occurred in CoronaVac-primed arms, but we did not identify overall differences between vaccine groups in $CD4^+$ and $CD8^+$ T cell responses. When Omicron BA.2 was circulating, we identified 58 infections with cumulative incidence of 15.3% and 15.4% in the CC-C and CC-B (p=0.93), and 16.7% and 14.0% in the BB-C and BB-B arms, respectively (p=0.56).

Conclusions: Similar levels of incidence of infection in each arm suggest all third dose combinations may provide similar degrees of protection against prevalent Omicron BA.2

67   infection, despite very weak antibody responses to BA.2 in the recipients of a CoronaVac third

68   dose. Further research is warranted to identify appropriate correlates of protection for inactivated

69   COVID-19 vaccines.

INTRODUCTION

The accrual of population immunity to COVID-19 may ultimately allow communities to return to normal, or at least to a "new-normal". Immunity can be acquired through surviving infections or, preferably, by vaccination. An unprecedented global effort has led to the rapid development and deployment of COVID-19 vaccines.[1] Vaccines against COVID-19 have generally been developed initially as either a single dose, or two doses of the same vaccine technology platform i.e. a homologous two-dose regimen.[1] The emergence of variants of concern (VOCs)[2] and observed decrease in vaccine-induced immune responses within a few months after vaccination[3,4] have led to the implementations of third dose ("booster") vaccination programs.[5] While some booster campaigns have encouraged individuals to receive a homologous third dose, a third/booster dose with a different vaccine platform, i.e., heterologous vaccination, could be more feasible in some locations.[6-8] There is also a possibility that combining vaccine doses using different vaccine platforms by heterologous prime-boost strategies might enhance the immune response.[9] Heterologous vaccination has been investigated by a number of clinical trials with mixed results depending on the initial platform and sequence of vaccination.[7,10,11] Conversely, considerations over adverse events may prompt individuals to prefer one vaccine platform over the other.[8]

In Hong Kong, a subtropical city in southern China, the COVID-19 vaccination programme started in February 2021. The programme initially offered each adult in Hong Kong a choice of two doses of the inactivated whole-virion vaccine CoronaVac (Sinovac) 28 days apart, or two doses of mRNA vaccine BNT162b2 (BioNTech/Fosun Pharma, marketed by Pfizer outside China) 21 days apart, with broad eligibility criteria and availability. Subsequently, healthy adults

have been recommended to receive a third dose of either vaccine (i.e., allowing cross-over) as

soon as 90 days after the second dose.[8]

Safety, immunogenicity and efficacy are the main aspects evaluated before vaccines are licensed.

There are few trials[12] comparing the potential advantages of homologous or heterologous third

doses in individuals who have previously received two doses of an inactivated vaccine or two

doses of an mRNA vaccine. Here, we conducted a randomized trial to compare the

immunogenicity and reactogenicity to BNT162b2 or CoronaVac in individuals that had

previously received two doses of those vaccines. In addition, in early 2022 during the biggest

local (fifth) wave the antigenically distinct Omicron BA.2 variant was the major circulating

strain,[13] which provided us an opportunity to evaluate the comparative efficacy of these different

vaccine combinations against infection.

METHODS

Trial design and participants

This study is an open-label randomized trial conducted in Hong Kong to measure the vaccine

(humoral) immunogenicity and reactogenicity of third doses with an mRNA vaccine

(BNT162b2) or an inactivated vaccine (CoronaVac) in adults who have previously received two

doses of either vaccine. BNT162b2 is a nucleoside-modified mRNA encoding the trimerized

SARS-CoV-2 spike glycoprotein formulated in lipid nanoparticles, and each 0.3mL dose

contains 30μg of mRNA. CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted, β-

propiolactone-inactivated vaccine, and each 0.5 ml dose includes 600SU of inactivated SARS-

CoV-2 virus.

Individuals were eligible for this study if they were Hong Kong residents, ≥18 years of age at

enrolment and had previously received a homologous two-dose primary series of either

BNT162b2 or CoronaVac, with the second dose received at least 6 months (180 days) earlier.

Exclusion criteria included: a history of confirmed SARS-CoV-2 infection, a delay of ≥43 days

between the first two vaccine doses, contraindication for COVID-19 vaccination such as severe

allergies, use of medication that could impair the immune system in the last 6 months (except

topical steroids or short-term oral steroids), use of immunoglobulins and/or any blood products

within 90 days prior to enrolment, and pregnant or nursing, or planning to become pregnant. The

study protocol (Clinicaltrials.gov NCT05057169) was approved by the Institutional Review

Board of the University of Hong Kong (ref: UW 21-492).

Randomization and masking

The random allocation process was concealed from both participants and the field investigation

team, by way of pre-assignment based on a computer-generated sequence of random numbers

administered by clicking a randomization button in the online data collection tool REDCap. We

used a block randomization structure with block sizes of 2, 4 and 6. The sequence of random

numbers was generated prior to the start of the study by a statistician using the computer

software package R. For logistical reasons individuals were randomized at the time vaccination

appointments were made, and there were dropouts after randomization and before vaccination.

However, both the participants and field investigation team were not aware of the intervention

until after vaccination, as the vaccination was done by separate unblinded nurses at the

community vaccination centres. After vaccination, participants were provided with vaccination

cards as required by the local government indicating which vaccine they had received, i.e.

participants and field investigation team were also unblinded from this time onwards. The staff

conducting laboratory tests were blinded to the third dose allocation.

Procedures

Participants were enrolled from the general community (see **Supplementary Information** for

additional information on enrolment and follow-up). We collected 20ml blood samples

immediately prior to vaccination (Day 0) and scheduled follow-up blood draws at 28, 182 days

and 365 days after vaccination. In a voluntary subset of approximately 35% of participants we

collected additional 10ml whole blood samples at day 0, 7 and 28 for analysis of cell-mediated

immune responses (CMI). At each encounter for a blood draw we offered a HKD100 (USD13)

incentive in the form of a supermarket gift voucher. After vaccination, participants were

provided with vaccination cards and tympanic thermometers, observed for 15-30 minutes for

immediate events, and then provided with an e-diary and requested to record daily on possible

(delayed) adverse events or symptoms for 7 days as well as any medical encounters. From March

2022, all participants were invited to participate in active surveillance to identify COVID-19 and

influenza virus infection using rapid antigen tests (RAT) at home every four days. We also

ascertained whether any participants had an infection identified by RAT or PCR after enrolment

but prior to the start of active surveillance. The active surveillance is continuing with information

collected up to May 31 included in the present analyses.

Outcomes

The primary outcome measure is the immunogenicity at 28 days after the third dose of either BNT162b2 or CoronaVac, measured as geometric mean titer (GMT) of SARS-CoV-2 serum neutralising antibodies using plaque reduction neutralization test ($PRNT_{50}$). The secondary outcome measures included i) the geometric mean fold rise (MFR) of SARS-CoV-2 serum neutralising antibody titers from baseline (Day 0) to Day 28, ii) magnitude and phenotype of vaccine-specific $IFN\gamma^+CD4^+$ and $IFN\gamma^+CD8^+$ T-cell responses at Day 7 and 28, iii) the incidence of solicited local and systemic adverse events, and iv) COVID-19 infections after receiving the third vaccine dose.

Sample size justification

For the primary outcome of vaccine immunogenicity, i.e. the GMT of SARS-CoV-2 serum neutralising antibodies against the vaccine strain (ancestral virus) at 28 days after vaccination, a sample size of 100 individuals in each study arm was chosen. Based on our preliminary data, assuming $log_{10}(GMT(PRNT_{50}$ at Day 0$)) = log_{10}(27) = 1.4$ with a standard deviation of 0.9, a sample size of 80 individuals per group would provide 80% power to detect a difference in log_{10} GMT of 0.4 or greater at the 5% significance level. The same calculation applies in each stratum. We aimed for at least 100 individuals in each study arm to allow for the possibility of withdrawal from the study prior to the day 28 assessment.

Laboratory analysis

Blood samples were delivered to our study laboratory at the University of Hong Kong as soon as possible, with the optimal delivery time within 24h. Clotted blood samples were stored in a

refrigerated container at 2-8°C immediately after collection and while in transit to the central

laboratory. Sera were extracted from the clotted blood samples within 48 hours after collection,

divided into 2-4 aliquots, and stored at -80°C until subsequent serologic testing. Heparinized

blood samples were kept at room temperature upon collection and while in transit and processed

within 24 hours of collection. Peripheral blood mononuclear cells (PBMCs) were isolated from

the heparinized (whole) blood using Ficoll-Paque and leucosep tubes, divided into 2 aliquots,

and cryopreserved in liquid nitrogen until further analysis for cell-mediated immune responses.

Details of serologic testing, including our in-house enzyme-linked immunosorbent assay

(ELISA) for the receptor binding domain (RBD) of the spike protein, a surrogate virus

neutralisation test (sVNT) (GenScript) and a plaque reduction neutralisation test (PRNT), have

been described in our earlier study on the immunogenicity of third-dose BNT162b2 after two

doses of CoronaVac[8]. We aimed to test sera collected on Day 0 and 28 with ELISA against

ancestral virus and sVNT against both ancestral virus and Omicron variant in all participants,

and with PRNT against both ancestral virus and Omicron variant in a randomly selected subset

of 20 participants in each study arm. We have demonstrated a good correlation (r=0.77) between

$PRNT_{50}$ and sVNT neutralization percentage for ancestral virus in our earlier studies[14]. The

ELISA has a dynamic range of between 0 to 5, although it was not designed as a quantitative

assay. For ELISA a single 1:100 serum dilution and for sVNT a single 1:10 serum dilution was

tested respectively. For PRNT, a serial two-fold serum dilutions from 1:10 to 1:320 were tested

initially, and in participants with an initial $PRNT_{50}$ titer of ≥320, additional PRNT using a serial

two-fold serum dilutions from 1:40 to 1:1280 were performed. PRNT assays were carried out

using ancestral SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020 (GISAID

EPI_ISL_412028) isolated in Vero-E6 cells (ATCC CRL-1586), the Pango lineage B.1.1.529

Omicron BA.1 subvariant designated hCoV-19/Hong Kong/VM21044713_WHP5047-S5/2021

(GISAID EPI_ISL_6716902) and BA.2 subvariant hCoV-19/Hong

Kong/VM22000135_HKUVOC0588P2/2022 (GISAID EPI_ISL_9570707) isolated in Vero-E6

TMRSS2 cells (Vero E6 cells overexpressing TMPRSS2, kindly provided by Dr S Matsuyama

and colleagues),[15] and the passage level 3 virus aliquots were used. Cells were maintained in

DMEM medium supplemented with 10% FBS and 100 U/ml penicillin–streptomycin (all from

ThermoFisher Scientific, Waltham, MA, USA). The $PRNT_{50}$, $PRNT_{80}$ and $PRNT_{90}$ titers were

the highest serum dilutions neutralising $\geq 50\%$, $\geq 80\%$ and $\geq 90\%$ of input plaques, respectively.

The WHO control serum provided by the National Institute for Biological Standards and Control

20/136 gave $PRNT_{50}$ titers of 320 and 320 against the ancestral virus and 20 and 40 against the

Omicron variant in two titrations.

The cell-mediated immune responses to the third dose COVID-19 vaccination, proxy by the

cytokine production of IFNγ (in both CD4$^+$ and CD8$^+$ T cells) or IL4 (in CD4$^+$ T cells only) of T

cells, were assessed in a randomly-selected subset of 20 participants in each study arm by

intracellular cytokine staining (ICS). All testing was done in two experiments with each

experiment including 10 participants randomly selected from each study arm, and time point

samples collected from the same participant tested in parallel in the same experiment. Samples

with a positive value after subtracting the respective value of the DMSO control were classified

as having a positive response ("responder") (value of DMSO control for CD4$^+$ IFNγ^+ T cells:

0.001%; CD8$^+$ IFNγ^+ T cells: 0.00017%; CD4$^+$ IL4$^+$ T cells: 0.000039%). Furthermore, CD4$^+$

and CD8$^+$ T cell memory phenotypes (CD45RA/CD27) and cytokine polyfunctional quality

(TNFα/IL2) were assessed by gating on IFNγ$^+$ cells for samples which were classified as CD4$^+$

IFNγ$^+$ T cell or CD8$^+$ IFNγ$^+$ T cell responders[16]. Cryopreserved PBMCs collected on Day 0, 7

and 28 were thawed and re-stimulated with an overlapping peptide pool representing the SARS-

CoV-2 structural proteins (spike, nucleocapsid, envelope and membrane) (300nM) or DMSO

(1% in RPMI) in two independent experiments. Cells were stimulated for a total of 28 hours at

37ºC. Golgi Plug (BD) containing Brefeldin A (1% in PBS), and Golgi Stop (BD) containing

Monensin (0.67% in PBS) was added at 24 hours during stimulation for further 4-hour

incubation. The amino acid sequence of the peptide pools was based on βCoV/Hong

Kong/VM20001061/2020 strain (GISAID ID: EPI_ISL_412028). Cells were stained with

Zombie-NIR (all antibodies from Biolegend and clone used) followed by anti-human CD3-

PE/Dazzle 594 (UCHT1), CD4-BV605 (OKT4), CD8-AlexaFluor700 (SK1), CCR7-

PerCP/Cy5.5 (G043H7), PD-1-BV421 (NAT105), CD45RA-APC (HI100), and a dump channel

containing CD19-BV510 (HIB19), CD56-BV510 (5.1H11) and CD14-BV510 (M5E2).

Following cell permeabilization, intracellular staining with anti-IFNγ-FITC (4S.B3), IL4-PE

(MP4-25D2) and TNFα-BV711 (MAb11), IL2-PECy7 (MQ1-17H12), was carried out before

acquisition of samples. Stained cells were acquired via flow cytometry (AttuneNxT) and

analysed by FlowJo v10. All samples met the cell viability cut-off of at least 30% and thus have

been included in the analyses.

Statistical analysis

We included all available data on participants who received a third dose of vaccination in our

trial. For post-vaccination reactions, solicited local and systemic events or symptoms were

presented as frequency (%) among participants who reported health status for ≥7 days in the

week following receipt of the third dose. We compared the proportions of the participants with adverse events between the two study arms in individuals who had a prior recipient of two-dose BNT162b2, or who had a prior recipient of two doses of CoronaVac, using the Chi-squared test or Fisher's exact test. Severity score as a proxy of interference to usual activities was calculated by assigning 0-reactions absent, 1-mild, 2-moderate and 3-severe and taking the average over the week after vaccination, and compared between groups using Student's t-tests.

For antibody responses, for sVNT measured negative neutralization percentages were transformed to zero. PRNT titers were taken as the reciprocal of the serum dilution and were interval-censored, e.g. a sample that was able to neutralise virus at a 1:20 dilution but not at a 1:40 dilution was reported as 20 to indicate that the titer was $\geq$20 and <40. We estimated the arithmetic mean of SARS-CoV-2 surrogate virus neutralization percentages and concentrations of SARS-CoV-2 Spike RBD IgG (proxy by OD_{450}) on Day 28. For PRNT titers, we imputed titers <10 with the value 5 and titers $\geq$1280 with the value 2560, and then transformed to $\log_2$ scale for the estimation of GMT and MFR, and significant testing. We compared antibody levels between Day 0 and Day 28 using Wilcoxon signed rank tests. We compared antibody levels at Day 28 between study arms using Mann-Whitney U tests. For cell-mediated response, we transformed $CD4^+$ $IFN\gamma^+$ T cell, $CD8^+$ $IFN\gamma^+$ T cell and $CD4^+$ $IL4^+$ T cell responses to log10 scale for the estimation of geometric means and fold-rises and significance testing. $CD4^+$ and $CD8^+$ T cell memory phenotypes and cytokine polyfunctional quality were assumed zeros for $CD4^+$/$CD8^+$ $IFN\gamma^+$ T cell non-responders. We compared T cell responses between Day 0 and Day 7, and between Day 0 and Day 28, using Wilcoxon signed rank tests. We compared T cell responses at Day 7, and at Day 28, between study arms using Mann-Whitney U tests.

We compared the cumulative incidence of infections in each study arm using Kaplan-Meier

curves and compared the incidence of infections using proportional hazards model. The

proportional hazards model was specified on a calendar time axis with follow up starting from

the start of Hong Kong's fifth wave on 1 January 2022 or on the date of third dose if later, and

ending at the earliest of the time of infection, the time of receiving a fourth dose, the time of

withdrawing from the study, or the censoring date on 31 May 2022. If a participant reported

more than one instance of positive result by RAT or PCR, the earliest date of identification was

considered the time of infection. All statistical analyses were conducted using R version 4.2.1 (R

Foundation for Statistical Computing, Vienna, Austria).

RESULTS

From 12 November 2021 through 27 January 2022, we screened 994 individuals and 818 (82%)

passed the initial eligibility assessment (**Figure 1, Figure S1**). We randomized 364 individuals

to the CC-C (178) and CC-B (186) arms, and 406 individuals to the BB-C (202) and BB-B (204)

arms. After final confirmation of eligibility, we collected baseline (Day 0) blood samples from

451 participants and then administered third doses, including 101 (57%) CC-C participants, 118

(63%) CC-B participants, 118 (58%) BB-C participants, and 114 (56%) BB-B participants.

Participant characteristics were generally comparable between the CC-C and CC-B arms, and

between the BB-C and BB-B arms (**Table 1**). Participants in the CC-C arm (median aged 58

years, IQR 50-64) were slightly older than those in CC-B (52 years, 43-58) (p = 0.01). For all

451 vaccinated participants, most reported receiving the second dose 6-8 months earlier (**Table**

1). A subset of 156 (35%) participants agreed to provide PBMCs samples on Day 0, 7 and Day

28 to evaluate cell-mediated immune responses ("CMI group").

We collected information on post-vaccination reactions in 424 (94%) participants, including 193

(64%) who reported ever feeling unwell after vaccination, with significantly more frequent

reactions in recipients of a third dose of BNT162b2 that mostly subsided within 7 days (**Figure**

2, **Table S3**). Fever $\geq 38.0^{\circ}$C was reported by about 10% of participants in both BB-B and CC-B

arms, but by none in BB-C and CC-C arms (**Table S3**). Among 440 participants who reported

information on medical care and hospitalisation, 10 reported seeking ambulatory care within one

month of the third dose, including 4 (1 in CC-C and 3 in CC-B) for discomfort associated with

vaccination (**Table S4**). One BB-B participant reported hospitalisation within a month of

vaccination for unrelated reasons (**Table S4**).

Third-dose vaccination significantly increased neutralising antibodies, measured as sVNT

inhibition percentage or PRNT$_{50}$ titers, against the ancestral virus, Omicron BA.1 and BA.2 on

Day 28 from baseline in all four study arms regardless of third dose vaccine type (**Figure 3,**

Figure S4, **Table S5**). In both assays, antibody responses to a BNT162b2 third dose were

substantially and statistically significantly greater than responses to a CoronaVac third dose

(**Figure 3, Figure S2A, Figure S4, Table S5**). Similar results were observed when comparing

binding antibodies by ELISA (**Figure S3, Table S6**).

In a subset of 20 participants randomly selected from each study arm (**Table S2**), we found that

vaccination significantly increased the number of IFNγ^{+} CD4^{+} T cells (indicative of a Th1

response) in both CC-C and CC-B arms on Day 7, which remained significantly elevated from

Day 0 on Day 28 (**Figure 4A**, **Figure S2B**). There was no significant change in $IFN\gamma^+ CD4^+$ T

cells in both BB-C and BB-B arms on both Day 7 and Day 28 (**Figure 4A**, **Figure S2B**).

Separately, 30-50% participants in all arms had $IFN\gamma^+ CD8^+$ T cells (indicative of a CTL

response) at baseline, but these were only significantly boosted in CC-B arm on Day 7 and

contracted by Day 28 (**Figure 4B**, **Figure S2B**). Meanwhile, $IL4^+ CD4^+$ T cells (indicative of a

Th2 response) were not significantly boosted by third doses in any arm (**Figure S2B, Figure**

S5). There were no significant differences in the magnitude of $CD4^+$ and $CD8^+$ T cell responses

between third doses of CoronaVac or BNT162b2 (**Table S6, Table S7**). We also evaluated the

multi-cytokine production ($TNF\alpha$ and IL-2) and memory phenotype of $IFN\gamma$-producing $CD4^+$ or

$CD8^+$ T cells. We observed a bias towards single cytokine responses ($IFN\gamma^+$) as the majority of

the T cell responses, but expansions upon vaccination of double cytokine responses ($IFN\gamma^+$ with

$TNF\alpha^+$ or $IL-2^+$) in CC-C and CC-B; and T effector memory responses predominated across all

arms and were further expanded in CC-C and CC-B (**Figure 4C and 4D, Table S5**).

We identified 58 SARS-CoV-2 infections by 31 May 2022, within 4-6 months of receipt of the

third dose of vaccination. During this period the Omicron BA.2 variant was locally circulating.

The number of infections identified by arm was 13/85 (15.3%) in CC-C, 16/104 (15.4%) in CC-

B, 16/96 (16.7%) in BB-C and 13/93 (14.0%) in BB-B arms, with no statistically significant

difference detected between the CC-C and CC-B arms (p = 0.93) nor between the BB-C and BB-

B arms (p = 0.56) (**Figure 5**). Comparing BB-B and BB-C groups, the hazard ratio for a

BNT162b2 third dose compared to a CoronaVac third dose was 0.80 (95% confidence interval:

0.39, 1.67) corresponding to a relative vaccine efficacy of 20%, while the hazard ratio for CC-B

versus CC-C was 0.97 (95% confidence interval: 0.47, 2.01) corresponding to a relative vaccine

efficacy of 3%. Additional information on active surveillance is available in **Supplementary**

Materials.

DISCUSSION

Here, we have conducted a comprehensive assessment of the reactogenicity, antibody response,

T cell responses and risk of infection in a randomised trial of homologous and heterologous

boosting with BNT162b2 and CoronaVac. Our population had minimal COVID-19 infection

history prior to all three doses of vaccination,[17] and absence of known prior COVID-19 infection

was one of the inclusion criteria. Furthermore, SARS-CoV-2 infection attack rate in the

population of Hong Kong assessed by population based sero-surveillance studies was

approximately 1% prior to the fifth wave of infections (unpublished data), thus likelihood of

unsuspected infection in this cohort prior to vaccination was low. When evaluating the ability to

boost immune response by a third vaccine dose, we showed that regardless of the combinations,

a third vaccine dose increased neutralising antibody against all ancestral virus, the Omicron

BA.1 and BA.2 variants significantly from baseline (**Figure 3**). The phenotype of the T cell

responses was predominantly effector memory and single cytokine producing across all vaccine

arms, but $CD4^+$ and $CD8^+$ T cell responses were only boosted in CC-C and CC-B, and no

differences were found between all arms in total magnitude of T cell responses, phenotype or

proportion responders (**Figure 4**). Prior influenza research has suggested the differentiation state

of T cell responses can impact recall potential at infection and protection from disease.[18] Thus,

mRNA vaccine as a booster substantially increased antibody response, and those primed with

two-dose inactivated vaccines by receiving mRNA or inactivated vaccine booster will benefit the

T cell response, each providing an immunological layer against COVID-19. These findings

suggest there is immune benefit of administering either a homologous or heterologous third dose

six months after the second dose, especially more prominent in adults who initially received two

doses of an inactivated vaccine.

The humoral and cellular immune results taken together would be indicative of superior efficacy

of a third dose of BNT162b2 but that is not what we observed (**Figure 5**). Rates of infection,

with Omicron BA.2 predominant in the community, were very similar among study arms

(**Figure 5**). This discrepancy may indicate the challenge of using neutralising antibody as a

correlate or mediator of protection against infection,[19,20] at least in comparisons between

vaccination strategies of mRNA and inactivated vaccines. Although neutralizing antibody did

appear to be a correlate of protection when comparing RNA and adenovirus vectored vaccines

and in comparisons between vaccinated and unvaccinated individuals,[21-23] antibody alone may

not explain the protection provided by inactivated vaccines, especially against viruses such as

Omicron which have high escape from neutralizing antibody elicited by ancestral virus. T-cell

responses may also play a role, as well as potentially non-neutralizing antibodies to internal virus

genes such as the nucleocapsid. A discordance between neutralizing antibody titres and vaccine

effectiveness against severe disease was also noted by us previously.[24] Such differences between

vaccine types may not always have been accounted for in immunobridging studies[25].

The $CD4^+$ helper T cell response, which has been shown to confer heterologous protection

against lung damage from infection by Beta variant in mice,[26] was significantly boosted and

maintained by both homologous (CC-C) and heterologous (CC-B) third dose after two doses of

inactivated vaccine (**Figure 4**). This is consistent with earlier findings,[27,28] and these studies

additionally suggested cross-reactivity against the Omicron variant by a third dose. Conversely,

there was no boost of T cell responses neither by a homologous nor heterologous third dose after

two doses of BNT162b2 (**Figure 4**), however a high level of responders at baseline was observed

in both arms (**Figure 4A and 4B**). The CD8$^+$ cytotoxic T cell response, which may have a role in

limiting COVID-19 disease severity,[29,30] was significantly boosted at Day 7 although not

maintained to memory (Day 28) by heterologous third-dose BNT162b2 after two doses of

CoronaVac (**Figure 4**). While the initial two doses were not randomized and participants did

differ in a number of ways (**Table S9**), more participants who previously received two-dose

BNT162b2 (80-90% responders) had CD4$^+$ T cell responses compared to those who previously

received two-dose CoronaVac (60-70% responders), and similar proportions of participants had

CD8$^+$ T cell response at baseline between all arms (30-50% responders, **Figure 4**). In addition,

the baseline CD4$^+$ T cell response of participants who received prior two doses of BNT162b2

were similar to the levels after third-dose vaccination in participants received prior two doses of

CoronaVac (**Figure 4**). These may suggest a ceiling effect on the T cell response among

participants who previously received two doses of BNT162b2 and explain the lack of boost in

cell-mediated immunity in the BB-C and BB-B arms, which has also been observed

elsewhere.[28,31]

Our study has several limitations. First, due to logistical challenges, we were only able to

randomise at the time vaccination appointment was made but not at vaccination, and nearly half

of randomized individuals dropped out before vaccination. However, the rates of dropout were

similar across study arms, and we have taken great care in the randomisation and allocation

concealment so that individuals dropping out were not aware of their allocated vaccine type.

Comparisons between study arms did not identify significant differences in most baseline

characteristics measured, except vaccinated participants in CC-B were on average 6 years

younger than those in CC-C, and vaccinated participants in BB-B were over twice more likely to

have hypertension than those in BB-C (**Table 1**). We also did not observe any significant

differences in all antibody and cell-mediated response measured at baseline (**Table S6**). Second,

in our study we did not include an unvaccinated control group, nor a two-dose comparison

group, to evaluate the additional benefits of third dose over existing two doses. Third, we have

only studied neutralising antibodies and T cell response, while other branches of immunity such

as non-neutralising antibodies[32,33] may also contribute to protection and may explain the

discrepancy in our immunologic and efficacy data. Finally, our study population consists of

adults whom first immune priming was from either mRNA or inactivated vaccination, which is

different to many parts of the world where the first immune priming was from natural infection.

This might lead to differences in subsequent immune response,[34] vaccine effectiveness[35] and

duration of protection,[36] and our study findings should be interpreted with these considerations.

In conclusion, our results suggest there is immune benefit in both administering a homologous or

heterologous third dose 6 months after two doses of inactivated or mRNA vaccination, with

similar levels of protection against infection provided by all four combinations. Mass vaccination

programmes that offer both inactivated and mRNA vaccines, with explanation on their potential

advantages and disadvantages, will help individuals in deciding their preferred option, allow

flexibility in vaccine deployment, and encourage vaccine uptake.[37] Our finding that neutralizing

antibody may not be the dominant correlate of protection for inactivated vaccines, especially

against SARS-CoV-2 variants such as Omicron that have significant capacity to evade

neutralizing antibody, needs to be considered in the development of "variant proof" COVID-19

vaccines or vaccines broadly protective against sarbecoviruses currently in development.[38]

REFERENCES

1. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity 2021;54:1636-51.

2. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021;397:2461-2.

3. Cowling BJ, Wong IOL, Shiu EYC, et al. Strength and durability of antibody responses to BNT162b2 and CoronaVac. Vaccine 2022;40:4312-7.

4. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 2021;398:385-7.

5. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med 2021;385:1393-400.

6. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2022;399:36-49.

7. Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix? The Lancet Infectious Diseases 2022;22:438-40.

8. Leung NHL, Cheng SMS, Martin-Sanchez M, et al. Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine. Clin Infect Dis 2022.

9. Dangi T, Class J, Palacio N, Richner JM, Penaloza MacMaster P. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep 2021;36:109664.

10.   Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19

Booster Vaccinations. N Engl J Med 2022;386:1046-57.

11.   Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous

COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19

vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet

2022;399:521-9.

12.   Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19

vaccine schedules—To mix or not to mix? Lancet Infect Dis 2022;22:438-40.

13.   Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2

Omicron BA.2 Variant, Hong Kong, January-March 2022. Emerg Infect Dis 2022;28.

14.   Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing

antibody responses after infection and estimates of the duration of protection. EClinicalMedicine

2021;41:101174.

15.   Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by

TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020;117:7001-3.

16.   Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of

BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 2022;27:301-10.

17.   Chen LL, Abdullah SMU, Chan WM, et al. Contribution of low population immunity to

the severe Omicron BA.2 outbreak in Hong Kong. Nat Commun 2022;13:3618.

18.   Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection

against symptomatic pandemic influenza. Nat Med 2013;19:1305-12.

19.   Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2

infection and COVID-19 disease. Immunol Rev 2022.

20.   Lim WW, Leung NHL, Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Distinguishing

Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop

Influenza Vaccines. Am J Epidemiol 2020;189:185-92.

21.   Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly

predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med

2021;27:1205-11.

22.   Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the

mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43-50.

23.   Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and

asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032-40.

24.   McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three

doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based

observational study. The Lancet Infectious Diseases 2022.

25.   ICMRA COVID-19 Vaccine development: Future steps Workshop. 2021. (Accessed

August 9, 2022, 2022, at https://www.icmra.info/drupal/en/covid-19/24june2021.)

26.   Kingstad-Bakke B, Lee W, Chandrasekar SS, et al. Vaccine-induced systemic and

mucosal T cell immunity to SARS-CoV-2 viral variants. Proc Natl Acad Sci U S A

2022;119:e2118312119.

27.   Chen Y, Chen L, Yin S, et al. The Third dose of CoronVac vaccination induces broad and

potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.

Emerg Microbes Infect 2022;11:1524-36.

28.   Jung MK, Jeong SD, Noh JY, et al. BNT162b2-induced memory T cells respond to the

Omicron variant with preserved polyfunctionality. Nat Microbiol 2022;7:909-17.

29.   Kedzierska K, Thomas PG. Count on us: T cells in SARS-CoV-2 infection and

vaccination. Cell Rep Med 2022;3:100562.

30.   Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol 2022;23:186-

93.

31.   Romero-Olmedo AJ, Schulz AR, Hochstätter S, et al. Dynamics of humoral and T-cell

immunity after three BNT162b2 vaccinations in adults older than 80 years. The Lancet

Infectious Diseases 2022;22:588-9.

32.   Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and

Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl

Med 2022;14:eabn9243.

33.   López-Muñoz AD, Kosik I, Holly J, Yewdell JW. Cell surface SARS-CoV-2

nucleocapsid protein modulates innate and adaptive immunity. Science Advances 2022;8.

34.   Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2

infection leads to robust humoral response and antibodies that effectively neutralize variants.

Science Immunology 2022;7.

35.   Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and

Vaccination on Symptomatic Omicron Infections. N Engl J Med 2022;387:21-34.

36.   Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19

Vaccination and Previous Infection. N Engl J Med 2022;386:1207-20.

37.   Sprengholz P, Eitze S, Korn L, Siegers R, Betsch C. The power of choice: Experimental

evidence that freedom to choose a vaccine against COVID-19 improves willingness to be

vaccinated. Eur J Intern Med 2021;87:106-8.

38.   Morens DM, Taubenberger JK, Fauci AS. Universal Coronavirus Vaccines — An Urgent

Need. N Engl J Med 2022;386:297-9.

Acknowledgements

We gratefully acknowledge colleagues including Teresa So, Justin Wan and Eileen Yu for

technical support in preparing and conducting this study; Anson Ho for setting up the database;

Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung

at HKU Health System; Cindy Man and other colleagues at the HKU Community Vaccination

Centres at Gleneagles Hospital; and all the study participants for facilitating the study.

Funding

This project was supported by the Health and Medical Research Fund (grant no. COVID19F09),

and the Theme-based Research Scheme of the Research Grants Council of the Hong Kong

Special Administrative Region, China (grant no. T11-705/21-N). BJC is supported by the

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department

of Health and Human Services, under contract no. 75N93021C00015, and a RGC Senior

Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the

Hong Kong Special Administrative Region, China. The funding bodies had no role in the design

of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.

Author contributions

All authors meet the ICMJE criteria for authorship. Each author's contributions to the paper are

listed below according to the CRediT model:

Conceptualization: NHLL, GML, BJC.

Methodology: NHLL, SMSC, CAC, JSMP, SAV, BJC.

Formal analysis: NHLL, CAC, MM-S, SAV, BJC.

Investigation: CAC, NYMA, LLHL, LCHT, KKHK, SC, LWCF, AWLC, KCKC, JKCL, YYN, PK, JZJ.

Funding acquisition: NHLL, GML, BJC.

Project administration: NHLL, SMSC, JSMP, SAV, BJC.

Supervision: NHLL, SMSC, DKMI, LLMP, JSMP, SAV, BJC.

Writing – original draft: NHLL, CAC, MM-S, JSMP, SAV, BJC.

Writing – review & editing: NHLL, SMSC, CAC, MM-S, NYMA, LLHL, LCHT, KKHK, SC, LWCF, AWLC, KCKC, JKCL, YYN, PK, JZJ, DKMI, LLMP, GML, JSMP, SAV, BJC.

Data availability

Data to reproduce the results shown here will be posted on github after peer review and publication of our article.

Competing interests

BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no other potential conflicts of interest.

Figure 1. Flow chart of participant enrolment for this open-label randomised trial of CoronaVac or BNT162b2 provided as a third vaccine dose in adults who previously received two doses of either vaccine. A more detailed flow chart with reasons for exclusion at each stage is provided in Supplementary Figure S1.

Figure 2. Solicited local and systemic reactions during the 7 days after a randomised third

dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of

either vaccine. For solicited systemic reactions only the most frequently reported reactions are

shown. The four study arms included participants who previously received two-dose CoronaVac

and were randomised to receive a third dose of CoronaVac ("CC-C") (red, left panel) or

BNT162b2 ("CC-B") (blue, left panel), and participants who previously received two-dose

BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") (red, right

panel) or BNT162b2 ("BB-B") (blue, right panel).

Figure 3. Serum neutralising antibodies against (A, D) ancestral SARS-CoV-2 virus, (B, E)

Omicron BA.1 and (C, F) Omicron BA.2 variants at baseline and 28 days after a

randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously

received two doses of either vaccine, measured by live virus plaque reduction

neutralization test (PRNT) or surrogate virus neutralization test (sVNT) respectively.

PRNT titers were evaluated with endpoint at 50% inhibition ($PRNT_{50}$). Data on PRNT was

available from a random subset of 20 participants selected from each study arm. The four study

arms included participants who previously received two-dose CoronaVac and were randomised

to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who

previously received two-dose BNT162b2 and were randomised to receive a third dose of

CoronaVac ("BB-C") or BNT162b2 ("BB-B"). The symbol X and the numbers above each panel

indicate the mean level. p-values ≤ 0.05 *, ≤ 0.01 **, ≤ 0.001 ***

Figure 4. CD4+ (A, C) and CD8+ (B, D) T cell responses against structural peptides of ancestral SARS-CoV-2 virus at baseline, and 7 and 28 days after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine, measured by (A, B) IFNγ production, (C, D) the ability to poly-cytokine production and memory phenotypes. Data was available from a random subset of 20 participants selected from each study arm. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). The dotted lines represent the lower limits of detection based on DMSO controls and participants with values above these thresholds are considered as responders: 0.001% for CD4+ IFNγ+ T cells and 0.00017% for CD8+ IFNγ+ T cells. The numbers above each panel indicate the mean level, while the percentages indicate the proportion of responder. p-values ≤ 0.05 *, ≤ 0.01 **, ≤ 0.001 ***

Figure 5. Cumulative incidence of SARS-CoV-2 infection after a randomised third dose of CoronaVac or BNT162b2 vaccine, in adults who previously received two doses of (A) CoronaVac or (B) BNT162b2, from after third-dose vaccination until 31 May 2022. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). SARS-CoV-2 infections were identified by rapid antigen test or PCR.

Table 1. Characteristics of all vaccinated participants at baseline. We enrolled adults who previously received two doses of CoronaVac or BNT162b2, and randomly assigned participants to receive either vaccine as a third dose, i.e. the four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a homologous third dose of CoronaVac ("CC-C") or a heterologous third dose of BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a heterologous third dose of CoronaVac ("BB-C") or a homologous third dose of BNT162b2 ("BB-B"). Differences with p-values ≤ 0.05 were highlighted in bold.

Characteristic	All enrolled and received third dose vaccination	Received two-dose CoronVac (CC)			Received two-dose BNT162b2 (BB)		
		Randomised to CoronaVac (CC-C)	Randomised to BNT162b2 (CC-B)	p-value	Randomised to CoronaVac (BB-C)	Randomised to BNT162b2 (BB-B)	p-value
	(N = 451)	(N = 101)	(N = 118)		(N = 118)	(N = 114)	
	n (%)	n (%)	n (%)		n (%)	n (%)	
Female	221 (49)	47 (47)	64 (54)	0.13	51 (43)	59 (52)	0.5
Age (median, IQR)	54 (47-60)	**58 (50-64)**	**52 (43-58)**	**0.01**	56 (47-60)	53 (46-59)	0.55
Age group (years)							
Underweight (BMI < 18.5)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	
Normal (BMI 18.5 – 22.9)	22 (5)	5 (5)	5 (4)		5 (4)	7 (6)	
Overweight (BMI 23.0 – 24.9)	38 (8)	8 (8)	13 (11)		8 (7)	9 (8)	
Obese (BMI ≥ 25.0)	100 (22)	13 (13)	34 (29)		27 (23)	26 (23)	
Underweight (BMI < 18.5)	173 (38)	36 (36)	45 (38)		47 (40)	45 (39)	

Normal (BMI 18.5 – 22.9)	99 (22)	33 (33)	20 (17)		28 (24)	18 (16)	
Overweight (BMI 23.0 – 24.9)	19 (4)	6 (6)	1 (1)		3 (3)	9 (8)	
Obese (BMI ≥ 25.0)	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	
Chinese	443 (98)	100 (99)	116 (98)	0.31	116 (98)	111 (97)	0.79
Obesity (for Asian populations)							
Underweight (BMI < 18.5)	23 (5)	6 (6)	6 (5)	0.97	4 (3)	7 (6)	0.6
Normal (BMI 18.5 – 22.9)	187 (41)	45 (45)	52 (44)		50 (42)	40 (35)	
Overweight (BMI 23.0 – 24.9)	99 (22)	20 (20)	22 (19)		28 (24)	29 (25)	
Obese (BMI ≥ 25.0)	142 (31)	30 (30)	38 (32)		36 (31)	38 (33)	
Chronic medical conditions							
Any	104 (23)	21 (21)	21 (18)	>0.99	30 (25)	32 (28)	0.9
Lung disease, including COPD and asthma	3 (1)	2 (2)	0 (0)	0.5	0 (0)	1 (1)	>0.99
Heart disease	5 (1)	2 (2)	1 (1)	>0.99	2 (2)	0 (0)	0.5
Hypertension	45 (10)	9 (9)	10 (8)	>0.99	**7 (6)**	**19 (17)**	**0.03**
Diabetes	13 (3)	6 (6)	2 (2)	0.29	3 (3)	2 (2)	>0.99
Hypercholesterolemia	28 (6)	7 (7)	3 (3)	0.34	9 (8)	9 (8)	>0.99
Kidney disease	1 (0)	0 (0)	0 (0)	>0.99	1 (1)	0 (0)	>0.99
Liver disease	7 (2)	1 (1)	2 (2)	>0.99	2 (2)	2 (2)	>0.99
Cancer	6 (1)	3 (3)	2 (2)	>0.99	0 (0)	1 (1)	>0.99

Days between first and second dose of COVID-19 vaccination (median, IQR)	27 (21-28)	28 (28-29)	28 (28-29)	0.59	21 (21-23)	21 (21-24)	0.63
Days between second and third (study) dose of COVID-19 vaccination (median, IQR)	232 (200-247)	236 (211-245)	236 (214-247)	0.51	226 (195-246)	222 (196-249)	0.98
Smoking							
Ever	20 (4)	8 (8)	7 (6)	>0.99	2 (2)	3 (3)	>0.99
Current	11 (2)	4 (4)	5 (4)	>0.99	1 (1)	1 (1)	>0.99